Zscaler Q4 Growth Steady at 25%, Forward Concerns Persist

What happened

Zscaler's fourth-quarter and full-year fiscal 2026 results showed revenue and ARR each growing 25% year over year, matching the prior quarter's pace and underscoring consistent top-line execution. However, the press release omits details on organic growth excluding the Red Canary acquisition, free cash flow margins, capital expenditure levels, or fiscal 2027 guidance, which were the primary concerns from our prior analysis. While management labels the results 'strong,' these headline figures likely include acquisition contribution and do not resolve the uncertainty around sales leadership turnover or reacceleration potential. The lack of forward-looking disclosures means the market will continue to scrutinize whether growth can sustain above the previously guided 16-17% for FY27. Consequently, the actual results neither confirm nor refute the investment thesis, leaving the stock's valuation dependent on upcoming detailed earnings commentary.

Implication

The Q4 results confirm Zscaler can sustain 25% headline growth, but the absence of details on organic growth, margins, and FY27 guidance keeps the stock in a prove-it phase. Investors should monitor the full earnings release and call for updates on sales leadership replacement, capex guidance, and any measurable AI disclosure. Until then, the base-case fair value of $155 and attractive entry near $135 from our prior report remain appropriate. A move above $180 would warrant trimming, while a drop below $135 could present a more favorable entry if execution concerns ease. Overall, the news does not warrant a change in conviction, and the WAIT rating stands.

Thesis delta

No material shift to the thesis: the Q4 results show stable 25% growth but do not address the key watch items of sales organization stabilization, FY27 guidance, or free cash flow sustainability. The prior WAIT rating, $135 attractive entry, and $180 trim level remain unchanged pending more detailed disclosures.